We thus designed a single-arm phase II trial to evaluate: i) the immune response after sequential treatment with RT and HD-IL-2 in patients with MM and RCC; ii) the safety of the treatment combination, the clinical response rate and the OS; iii) the role of immune biomarkers in predicting clinical response and prognosis. Here, IL2 is linked to Miyoshi myopathy.